Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been named CEO and Board [...]
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism®-NSCLC, an RNA-based diagnostic to [...]
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their PREDAPT clinical trial (NCT04510129) results in head and [...]
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today that Dr. Howard McLeod, Pharm.D., FASCO, FCCP, has been appointed to [...]
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today that Medicare contractor Palmetto GBA has granted national coverage for [...]
Twenty-five institutions collaborate with Cofactor to validate OncoPrism for use in head and neck cancer patients.
In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in [...]
Jarret Glasscock, PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. Precision [...]
Readout from the national PREDAPT multicenter clinical trial presented at AGBT Precision Health Conference Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results [...]
Sign up to receive the latest from Cofactor right in your inbox.
Start typing and press Enter to search
